<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603444</url>
  </required_header>
  <id_info>
    <org_study_id>0032443/15</org_study_id>
    <nct_id>NCT03603444</nct_id>
  </id_info>
  <brief_title>Reliability of Serum Calcium to Phosphorus (Ca/P) Ratio as an Accurate and Inexpensive Tool to Define Disorders of Ca-P Metabolism</brief_title>
  <official_title>Serum Calcium to Phosphorus (Ca/P) Ratio to Define Disorders of Ca-P Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Modena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder.&#xD;
      The Ca/P ratio is an accurate tool to differentiate patients with PHPT (&gt;3.5 if Ca and P are&#xD;
      expressed in mg/dl) from healthy subjects. The reliability of this index is based on the fact&#xD;
      that serum Ca and P are inversely related together. However, other disorders of the Ca-P&#xD;
      metabolism, such as hypophosphoremia (HypoP) not related to PHPT, might also impair the Ca/P&#xD;
      ratio.&#xD;
&#xD;
      OBJECTIVE: To validate the accuracy of Ca/P ratio in the diagnosis of Ca-P metabolism&#xD;
      disorders, including also patients with documented HypoP not related to PHPT.&#xD;
&#xD;
      METHODS: A single-center, retrospective, case-control study will be carried out.&#xD;
&#xD;
      Biochemical measurements will include parathormone (PTH), vitamin D, serum Ca and P, serum&#xD;
      albumin and creatinine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Calcium to Phosphorus ratio</measure>
    <time_frame>Assessed only once at the diagnosis (from January 2005 to January 2018)</time_frame>
    <description>Calculated formula (serum calcium to serum phosphorus ratio)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>Assessed only once at the diagnosis (from January 2005 to January 2018)</time_frame>
    <description>From blood sample - Unit of measurement: mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphorus</measure>
    <time_frame>Assessed only once at the diagnosis (from January 2005 to January 2018)</time_frame>
    <description>From blood sample - Unit of measurement: mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Parathormone</measure>
    <time_frame>Assessed only once at the diagnosis (from January 2005 to January 2018)</time_frame>
    <description>From blood sample - Unit of measurement: pg/ml</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">606</enrollment>
  <condition>Phosphorus and Calcium Disorders</condition>
  <arm_group>
    <arm_group_label>First study group: patients with PHPT</arm_group_label>
    <description>Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.&#xD;
Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) &lt;30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI &gt; 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second study group: patients with HypoP</arm_group_label>
    <description>Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.&#xD;
Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) &lt;30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI &gt; 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.&#xD;
Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) &lt;30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI &gt; 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention are provided</intervention_name>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>First study group: patients with PHPT</arm_group_label>
    <arm_group_label>Second study group: patients with HypoP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Serum Calcium to Phosphorus ratio will be compared among patients with different disorders&#xD;
        of calcium-phosphorus metabolism (primary hyperparathyroidism and hypophosphoremia) and&#xD;
        controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with diagnosis of primary hyperparathyroidism&#xD;
&#xD;
          -  HIV-infected patients with reduced phosphorus but normal calcium&#xD;
&#xD;
          -  subjects with normal Calcium-Phosphorus metabolism&#xD;
&#xD;
        Exclusion criteria for both cases and controls will be:&#xD;
&#xD;
          -  age younger than 18 or older than 90 years&#xD;
&#xD;
          -  severe renal and liver diseases (i.e. glomerular filtration rate (GFR) &lt;30 ml/min)&#xD;
&#xD;
          -  hyperparathyroidism secondary to Vitamin D deficiency&#xD;
&#xD;
          -  active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia,&#xD;
             rickets, etc)&#xD;
&#xD;
          -  any type of cancer&#xD;
&#xD;
          -  malnutrition&#xD;
&#xD;
          -  severe obesity (BMI &gt; 40 kg/m2)&#xD;
&#xD;
          -  a history of gastrointestinal malabsorption&#xD;
&#xD;
          -  sarcoidosis&#xD;
&#xD;
          -  hypercortisolism&#xD;
&#xD;
          -  diabetes insipidus&#xD;
&#xD;
          -  hyperthyroidism&#xD;
&#xD;
          -  pseudohypoparathyroidism&#xD;
&#xD;
          -  familial hypocalciuric hypercalcemia (FHH)&#xD;
&#xD;
          -  treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc),&#xD;
             thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Modena</investigator_affiliation>
    <investigator_full_name>Vincenzo Rochira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

